Advertisement

Clinical and Translational Oncology

, Volume 18, Issue 9, pp 884–892 | Cite as

Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain

  • A. Gómez CaamañoEmail author
  • A. Zapatero
  • J. López Torrecilla
  • X. Maldonado
Research Article

Abstract

Purpose

To define usual clinical management of prostate cancer (PCa) patients following postoperative radiation therapy (RT) (adjuvant or salvage) and its evolution over time in radiation oncology (RO) departments in Spain.

Methods

An epidemiological, cross-sectional, multicentre study was conducted. 567 PCa patients that had undergone radical prostatectomy (RP) and received postoperative RT between February and December of both 2006 and 2011 participated in the study. In patients from 2006, health-related quality of life (HRQoL) was assessed using the EPIC questionnaire. Investigators completed a specific survey on two clinical cases of adjuvant and salvage RT.

Results

70.6 % of patients received salvage RT versus 29.4 % who received adjuvant RT; no significant differences were found in terms of frequency for each procedure between both the years. Regarding the survey, a positive surgical margin was the main criteria used in adjuvant RT decision making. In terms of salvage RT scenario, 85.7 % of the investigators stated that adjuvant RT should have been offered instead, 81.4 % of the investigators agreed on a PSA score >0.2 ng/mL as the main criteria for identifying biochemical recurrence after RP, and 67.4 % of investigators did not consider any PSA score for ruling out salvage RT treatment.

Conclusions

Most patients are referred to RO departments to receive salvage RT. Despite the publication of three IA evidence level randomized clinical trials, the patterns for using adjuvant and salvage RT did not change from 2006 to 2011, although patients’ profile did. A consensus regarding postoperative RT indications should be reached in order to correct this controversial situation.

Keywords

Prostate cancer Prostatectomy Radiation therapy Adjuvant Salvage 

Notes

Acknowledgments

The authors would like to thank the following investigators for participating in the study: Algás Algás, Amparo Rosa; Álvarez González, Ana Mª; Andreu Martínez, Francisco José; Anglada Tort, Luís; Béjar Luque, Amelia; Biete Solá, Alberto; Boladeras Inglada, Ana Mª; Cabeza Rodríguez, Mª Ángeles; Cabrera Roldán, Patricia; Cantalapiedra del Pie, Mª del Rocío; Carballo Castro, Ana; Castillo Pérez, Isabel; Conde Moreno, Antonio José; Couñago Lorenzo, Felipe; del Cerro Peñalver, Elia; Escó Barón, Ricardo; Escribano Uzcudun, Ana; Ferrer Albiach, Carlos; Ferrer Albiach, Eduardo; Ferrer González, Ferrán; Foro Arnalot, Palmira; García Alonso, Elena; García Fernández, Ramón; Gómez Gómez, David; Gómez Heras, Laura; Gómez-Iturriaga, Alfonso; González Acosta, Pedro María; González San Segundo, Carmen; González Suárez, Herminio; Guerrero Grande, Araceli; Hervás Morón, Asunción; Ibáñez Villoslada, Carmen; Jiménez Salas, Rocío; Jové Teixido, Josep; López Campos, Fernando; López Soler, Francisco Javier; Lorente Sánchez, María; Lozano Galán, Joan; Ludeña Martínez, Blanca; Macías Hernández, Víctor; Mariño Cotelo, Alfonso; Mañas Rueda, Ana; Márquez García-Salazar, Mª Magdalena; Martín de Vidales, Carmen; Martínez Agra, Marta; Matute Martín, Raúl; Mira Flores, Moisés; Mira López, Jorge; Muñoz García, Julia Luísa; Nagore Cia, Gorka; Olivera Vegas, Jesús; Ossola Lentati, Gustavo; Otero, Ana; Palacios Eito, Amalia; Pastor Peidró, Jorge; Peleteiro Higuero, Paula; Pérez Casas, Ana Mª; Pinar Sedeño, Mª Beatriz; Prada Gómez, Pedro José; Puebla Díaz, Fernando; Ríos Asús, Patricia Viviana; Romero Rojano, Pilar; Rodríguez Liñán, Milagrosa; Rodríguez Villalba, Silvia; Rodríguez Zapatero, Ignacio; Samper Ots, Mª Pilar; Sánchez Saugar, Emilio; Sancho Pardo, Gemma; Soria Carreras, Pedro; Tormo Ferrero, Vicente; Tormo Micó, Alejandro; Trilla Martín, Jorge; Tripero Oter, Juana; Velilla Millán, Carmen; Villafranca Iturre, Elena; Viñals Montes, Pedro; Willisch Santamaría, Patricia; Zapata Paz, Irma.

Compliance with ethical standards

Disclosure of potential conflicts of interest

This study was funded by Astellas Pharma, SA, who also funded the logistics and technical support of IMS Health®. Authors claim having received honoraria from Astellas Pharma for conducting the study.

Research involving human participants and/or animals

The present study involved human participants, and it was conducted considering ethic responsibilities according to the World Medical Association and the Declaration of Helsinki.

Informed consent

All participants were informed of the study methodology and gave written informed consent prior to their inclusion in the study.

References

  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMedGoogle Scholar
  2. 2.
    Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Villavicencio H, Cantalapiedra A, et al. Registro nacional de cáncer de próstata 2010 en España. Actas Urol Esp. 2013;37:12–9.PubMedGoogle Scholar
  3. 3.
    Reis LO, Sasse AD, Matheus WE, Denardi F, Stopiglia RM, da Silva MM, et al. Cáncer de próstata: práctica clínica basada en la evidencia. Actas Urol Esp. 2009;33:344–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Bottke D, de Reijke TM, Bartkowiak D, Wiegel T. Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer. 2009;45:148–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013;190:441–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Mengual-Cloquell JL, Escolar-Pérez PP, Casaña-Giner M, Chust-Vicente ML, Guinot-Rodríguez JL, Arribas-Alpuente L. Tratamiento adyuvante y de rescate tras prostatectomia radical. Actas Urol Esp. 2005;29:553–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radial Oncol Biol Phys. 2008;72:972–9.CrossRefGoogle Scholar
  8. 8.
    Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC Trial 22911). Lancet. 2005;366:572–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;15(296):2329–35.CrossRefGoogle Scholar
  10. 10.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol. 2009;181:956–62.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–41.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–32.CrossRefPubMedGoogle Scholar
  14. 14.
    López Torrecilla J, Zapatero A, Herruzo I, Calvo FA, Cabeza MA, Palacios A, et al. Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer. Clin Transl Oncol. 2014;16:447–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186:865–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200.PubMedGoogle Scholar
  17. 17.
    Lavallée LT, Fergusson D, Mallick R, Grenon R, Morgan SC, Momoli F, et al. Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists. PLoS One. 2013;8:e79773.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Showalter TN, Ohri N, Teti KG, Foley KA, Keith SW, Trabulsi EJ, et al. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82:e233–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013;86:822–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway MS. Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. J Clin Oncol. 2002;20:1853–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Quon H, Suderman D, Guilbert K, Lambert P, Bucher O, Ong A, et al. Population-based referrals for adjuvant radiotherapy after radical prostatectomy in men with prostate cancer: impact of randomized trials. Clin Genitourin Cancer. 2014;12:e1–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011;185:116–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Izawa JI. Salvage radiotherapy after radical prostatectomy. Can Urol Assoc J. 2009;3:245–50.PubMedPubMedCentralGoogle Scholar
  24. 24.
    De Torres MV, Álvarez A, Ibáñez C, Caballero B, Ludeña B, Caballero P. Radioterapia adyuvante después de prostatectomía radical como tratamiento preventivo de la recidiva bioquímica. Arch Esp Urol. 2012;65:122–30.Google Scholar
  25. 25.
    Chen C, Lin T, Zhou Y, Li D, Xu K, Li Z, et al. Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis. PLoS One. 2014;9:e104918.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys. 2008;71:346–50.CrossRefPubMedGoogle Scholar
  27. 27.
    King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84:104–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Parker C, Sydes MR, Catton C, Kynaston H, Logue J, Murphy C, et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007;99:1376–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy—Adjuvant Versus Early Salvage (RAVES) trial. BJU Int. 2014;113:S7–12.CrossRefGoogle Scholar
  30. 30.
    Sowerby RJ, Gani J, Yim H, Radomski S, Catton C. Long-term complications in men who have early or late radiotherapy after radical prostatectomy. Can Urol Assoc J. 2014;8:253–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  • A. Gómez Caamaño
    • 1
    Email author
  • A. Zapatero
    • 2
  • J. López Torrecilla
    • 3
  • X. Maldonado
    • 4
  1. 1.Servicio de Oncología Radioterápica Hospital Universitario de Santiago de CompostelaCompostelaSpain
  2. 2.H. Universitario de La Princesa de MadridMadridSpain
  3. 3.H. General Universitario de ValenciaValenciaSpain
  4. 4.H. Universitari Vall d’Hebron de BarcelonaBarcelonaSpain

Personalised recommendations